Glenmark commences Phase II study of GBR 500 for ulcerative colitis
The randomised, double-blind, placebo-controlled study will evaluate the efficacy and safety of GBR 500 in patients with moderate to severe UC. Glenmark Pharmaceuticals chief scientific officer Dr. Michael